UPCC 13419: An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to evaluate the safety, recommended dose, antitumor activity, and pharmacokinetics of JCAR017 in subjects with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The safety of JCAR017 in subjects who are receiving concurrent ibrutinib will also be evaluated.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
08 May 2024.
Study ID: 832903
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
